Nanoviricides Stock Cash And Equivalents
| NNVC Stock | USD 1.59 0.01 0.63% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess NanoViricides' long-term financial health and intrinsic value.
NanoViricides | Cash And Equivalents | Build AI portfolio with NanoViricides Stock |
NanoViricides Company Cash And Equivalents Analysis
NanoViricides' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current NanoViricides Cash And Equivalents | 14.07 M |
Most of NanoViricides' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NanoViricides is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NanoViricides Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for NanoViricides is extremely important. It helps to project a fair market value of NanoViricides Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since NanoViricides' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NanoViricides' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NanoViricides' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
NanoViricides Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, NanoViricides has 14.07 M in Cash And Equivalents. This is 98.29% lower than that of the Biotechnology sector and 96.85% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.48% higher than that of the company.
NanoViricides Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NanoViricides' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NanoViricides could also be used in its relative valuation, which is a method of valuing NanoViricides by comparing valuation metrics of similar companies.NanoViricides is currently under evaluation in cash and equivalents category among its peers.
NanoViricides Current Valuation Drivers
We derive many important indicators used in calculating different scores of NanoViricides from analyzing NanoViricides' financial statements. These drivers represent accounts that assess NanoViricides' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NanoViricides' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 42.0M | 50.6M | 21.7M | 13.4M | 15.4M | 14.6M | |
| Enterprise Value | 29.4M | 30.2M | 7.7M | 5.2M | 6.0M | 5.7M |
NanoViricides Fundamentals
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 19.92 M | ||||
| Shares Outstanding | 16.07 M | ||||
| Shares Owned By Insiders | 3.50 % | ||||
| Shares Owned By Institutions | 7.87 % | ||||
| Number Of Shares Shorted | 105.96 K | ||||
| Price To Earning | (6.02) X | ||||
| Price To Book | 2.87 X | ||||
| EBITDA | (7.76 M) | ||||
| Net Income | (8.29 M) | ||||
| Cash And Equivalents | 14.07 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 1.36 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 34.92 X | ||||
| Book Value Per Share | 0.55 X | ||||
| Cash Flow From Operations | (6.32 M) | ||||
| Short Ratio | 0.40 X | ||||
| Earnings Per Share | (0.69) X | ||||
| Target Price | 6.5 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 25.39 M | ||||
| Total Asset | 12.82 M | ||||
| Retained Earnings | (139.37 M) | ||||
| Working Capital | 3.61 M | ||||
| Current Asset | 24.38 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 12.82 M |
About NanoViricides Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NanoViricides's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NanoViricides using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NanoViricides based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:Check out NanoViricides Piotroski F Score and NanoViricides Altman Z Score analysis. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.